Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Active, not recruiting · NCT04514419 · Registry updated 2025-11-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-11-21 | NCT04514419 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioRay Pharmaceutical Co., Ltd. | 9 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Affiliated Hospital of Qingdao University | Qingdao | China | 50 |